Back

Dual V1a/V2 versus selective V2 vasopressin receptor blockade in a preclinical heart failure model: does it matter?

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 7 - Heart failure / Left ventricular dysfunction Pharmacologic therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Thomas Mondritzki

Bayer AG, Wuppertal (Germany)

49 More presentations in this session

Presentation thumbnail
Survival in HFpEF vs HFrEF patients after beta-blocker titration: new insights from the CIBIS-ELD trial
Professor H. Duengen (Berlin, DE)
Presentation thumbnail
The use of Guideline recommended betablocker therapy in primary prevention ICD patients. Insight from Danish nationwide registries
Doctor A. Ruwald (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
The effect of angiotensin II type 2 receptor agonist treatment on doxorubicin induced heart failure
Associate Professor N. Ermis (Malatya, TR)
Abstract Slides
Presentation thumbnail
Triiodo-L-thyronine promotes the therapeutic efficacy for myocardial infarction of bone marrow mesenchymal stem cells
Professor S. Nie (Beijing, CN)
Abstract Slides
Presentation thumbnail
Vasodilator nicorandil in acute heart failure patients with aortic stenosis
Doctor K. Harada (Tokushima, JP)
Abstract

Access the full session

Session thumbnail
Poster session 7 - Heart failure / Left ventricular dysfunction

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources